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Background: Symptomatic relief is an important treatment goal for patients with COPD. To date, no diary for
evaluating respiratory symptoms in clinical trials has been developed and scientifically-validated according to FDA
and EMA guidelines. The EXACT – Respiratory Symptoms (E-RS) scale is a patient-reported outcome (PRO) measure
designed to address this need. The E-RS utilizes 11 respiratory symptom items from the existing and validated
14-item EXACT, which measures symptoms of exacerbation. The E-RS total score quantifies respiratory symptom
severity, and 3 domains assess breathlessness, cough and sputum, and chest symptoms.
Methods: This study examined the performance of the E-RS in each of 3 controlled trials with common and unique
validation variables: one 6-month (N = 235, US) and two 3-month (N = 749; N = 597; international). Subjects completed
the E-RS as part of a daily eDiary. Tests of reliability, validity, and responsiveness were conducted in each dataset.
Results: In each study, RS-Total score was internally consistent (Cronbach α) (0.88, 0.92, 0.92) and reproducible
(intra-class correlation) in stable patients (2 days apart: 0.91; 7 days apart: 0.71, 0.74). RS-Total scores correlated
significantly with the following criterion variables (Spearman’s rho; p < 0.01, all comparisons listed here): FEV1%
predicted (−0.19, −0.14, −0.15); St. George’s Respiratory Questionnaire (SGRQ) (0.65, 0.52, 0.51); Breathlessness,
Cough, and Sputum Scale (BCSS) (0.89, 0.89); modified Medical Research Council dyspnoea scale (mMRC) (0.40);
rescue medication use (0.43, 0.42); Functional Performance Inventory Short-Form (FPI-SF) (0.43); 6-minute walk
distance (6-MWT) (−0.30, −0.14) and incremental shuttle walk (ISWT) (−0.18) tests. Correlations between these
variables and RS-Breathlessness, RS-Cough and Sputum, RS-Chest Symptoms scores supported subscale validity.
RS-Total, RS-Breathlessness, and RS-Chest Symptoms differentiated mMRC levels of breathlessness severity (p < 0.0001).
RS-Total and domain scores differentiated subjects with no rescue medication use and 3 or more puffs (p < 0.0001).
Sensitivity to changes in health status (SGRQ), symptoms (BCSS), and exercise capacity (6MWT, ISWT) were also shown
and responder definitions using criterion- and distribution-based methods are proposed.
Conclusions: Results suggest the E-RS is a reliable, valid, and responsive measure of respiratory symptoms of COPD
suitable for use in natural history studies and clinical trials.
Trial registration: MPEX: NCT00739648; AZ1: NCT00949975; AZ 2: NCT01023516
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Respiratory symptoms, including breathlessness, cough,
and sputum production/expectoration, are defining fea-
tures of chronic obstructive pulmonary disease (COPD)
that can adversely affect patient functioning and quality
of life [1-10]. Symptomatic relief is often the patient’s
primary concern, an important treatment goal for clini-
cians, and a key outcome in clinical intervention trials.
With no known cure for COPD, effective symptom palli-
ation and exacerbation prevention are paramount.
The EXACT – Respiratory Symptoms (E-RS) scale was
designed to serve as a primary, secondary, or exploratory
endpoint in clinical trials evaluating the effect of treatment
on respiratory symptoms of COPD. The E-RS is based on
the 11 respiratory symptom items from the 14-item
EXACT, a daily diary used to measure exacerbations of
COPD [11-15] (see Additional file 1: Table E7). The E-RS
yields a total score, quantifying respiratory symptom sever-
ity overall, and 3 subscale scores assessing breathlessness;
cough and sputum; and chest symptoms. This permits 2
validated uses for a single diary: quantification of respira-
tory symptoms in stable COPD using E-RS total and
subscale scores and the assessment of acute exacerbations
(frequency, severity, duration of symptom-defined events,
and change in exacerbation symptoms with medically-
treated events) using the EXACT total score [15,16].
Good research practice and Food and Drug Administra-
tion (FDA) guidelines [17-19] for patient-reported outcome
(PRO) measures were followed during E-RS development
[15,17-19]. Qualitative research was performed to assess
content validity and reliability, validity, and sensitivity to
change were tested in data from a prospective naturalistic
study in the United States (US) [20]. To date, performance
properties of E-RS scores within the context of inter-
national randomized controlled trials (RCTs) had not been
established.
The objective of this study was to test the performance
of E-RS scores in each of 3 independent, international
RCTs evaluating 2 experimental drugs for the treatment
of COPD.
Methods
Study design, sample, and procedures
Pre-specified secondary analyses were performed on data
from 3 Phase II multi-centre, randomized, double-blind,
placebo-controlled trials. In each trial, patients were
enrolled during a stable state and completed the 14-item
EXACT daily diary as part of the trial procedures. These
datasets were also used to test the EXACT for evaluating
exacerbations of COPD that occurred during the course
of the trials [14].
The first dataset (Mpex) was a 6-month trial con-
ducted in the US testing MP-376 (Levofloxacin) Inhal-
ation Solution administered for 5 days every 28 days toprevent exacerbations in high risk COPD patients
(NCT00739648), with exacerbation rate over the study
period serving as the primary efficacy endpoint. Relevant
inclusion criteria were: age ≥40 years; post-bronchodilator
forced expiratory volume in 1 second (FEV1) ≤70% pre-
dicted and FEV1/forced vital capacity (FVC) ≤0.7; history
of 2 or more exacerbations the prior year; mucopurulent
sputum on most days, even when exacerbation-free; and
stable on long-acting bronchodilators and/or inhaled or
systemic steroids during the 30 day pre-baseline period.
Maintenance therapy for each patient was at the clinician’s
discretion.
Two datasets were from 12-week, parallel-group, multi-
national trials testing AZD9668 (a neutrophil elastase inhibi-
tor). AstraZeneca (AZ) 1 was dose-ranging with patients on
a baseline treatment of tiotropium (NCT00949975)
[21]. AZ 2 tested 1 dose against placebo, with patients
receiving budesonide/formoterol (NCT01023516) [22].
The primary efficacy endpoint for both trials was pre-
bronchodilator FEV1. Relevant inclusion criteria were:
age 40 to 80 years; post-bronchodilator FEV1% pre-
dicted 40%–80% (AZ 1) or 30%–80% (AZ 2); 1 or more
clinic visit or hospitalization for exacerbation the prior
year; Breathlessness, Cough, and Sputum Scale (BCSS)
score ≥2 per day for at least 7 of 14 days before enrol-
ment (Visit 2); and stable (no treatment, clinic visit or
hospitalization for exacerbation) for at least 4 weeks
prior to randomization.
Each study protocol stated that procedures adhered to
the Declaration of Helsinki and institutional review boards/
ethic committees approved the protocol(s) stipulating that
all subjects would provide written informed consent prior
to participation in the trial.
Due to differences in settings, maintenance therapies,
and criterion (validation) variables, no cross-study pool-
ing or analyses were planned or performed. Within each
trial, the experimental drug showed no treatment effects
on the primary or secondary endpoints. This allowed
pooling of data across treatment groups within each data-
base for the purpose of this psychometric validation, i.e.,
an examination of the performance properties of E-RS
scores in 3 independent, international samples of stable
patients with symptomatic, moderate to severe COPD
undergoing treatment with maintenance therapies.
Measures
All studies collected patient demographics, disease
history, and clinical data, with variance across trials. The
following assessments were relevant to these analyses.
Patient-reported measures
In each trial, participants completed an eDiary every
evening prior to bedtime that included the E-RS, as part
of the EXACT, and trial-specific assessments. Score
Table 1 Sociodemographic and clinical characteristics
Mpex AZ 1 AZ 2
(N = 235)* (N = 749)† (N = 597)‡
Age, mean (SD) 63.7 (8.95) 62.3 (8.25) 61.7 (8.27)
Gender, n (% Male) 113 (48.1) 572 (76.4) 443 (74.2)
Race/Ethnicity, n (%)
White 214 (91.1) 536 (71.6) 592 (99.2)
Asian 2 (0.9) 212 (28.3) 0 (0.0)
Black/African American 18 (7.7) 0 (0.0) 0 (0.0)
Hispanic or Latino 6 (2.6) 2 (0.3) 2 (0.3)
FEV1, mean (SD)
§ 1.2 (0.58) 1.7 (0.49) 1.6 (0.52)
FEV1% predicted, mean (SD) 42.2 (18.10) 58.8 (12.70) 54.2 (15.36)
GOLD¶ stage, n (%)
0 22 (9.4) 0 (0.0) 0 (0.0)
I 2 (0.9) 23 (3.2) 22 (3.8)
II 55 (23.4) 503 (69.1) 300 (51.9)
III 89 (37.9) 197 (27.1) 240 (41.5)
IV 66 (28.1) 5 (0.7) 16 (2.8)
SGRQ total score∥ 57.4 (16.21) 52.6 (18.36) 54.9 (17.14)
Exercise test meters, mean (SD) 289 (121)** 392 (122)** 337 (185)††
RS-Total Score, mean (SD)‡‡ 15.7 (5.93) 15.9 (6.0) 18.2 (5.99)
RS-Breathlessness 8.2 (5.93) 7.9 (3.17) 8.9 (3.12)
RS-Cough and Sputum 4.1 (2.08) 4.2 (1.56) 4.7 (1.60)
RS-Chest Symptoms 3.3 (2.08) 3.8 (1.93) 4.6 (1.91)
*United States.
†Australia, Canada, Germany, Japan, Korea, Philippines, Poland, Russia, Slovakia,
Taiwan, Ukraine, United States.
‡Bulgaria, Czech Republic, Hungary, Poland, Romania, Slovakia.
§Post-bronchodilator.
¶Spirometric classification GOLD 2014 [5].
∥Range: 0 to 100, higher scores = worse health status; SGRQ-C was used in
both AZ studies.
**6 Minute Walk Test (6MWT).
††Incremental Shuttle Walk Test (ISWT).
‡‡Baseline, mean (SD) weekly scores, Day −7 to Day 1; Ranges: RS-Total: 0 to 40;
RS-Breathlessness: 0 to 17; RS-Cough and Sputum: 0 to 11; RS-Chest Symptoms: 0
to 12; higher scores =more severe symptoms.
Abbreviations: AZ AstraZeneca, FEV1 forced expiratory volume in 1 second,
GOLD Global Initiative for Chronic Obstructive Lung Disease, SD standard
deviation, SGRQ St. George’s Respiratory Questionnaire, SGRQ-C St. George’s
Respiratory Questionnaire for COPD.
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severe symptoms. Participants in the Mpex trial also
recorded daily global health ratings; those in the AZ
trials completed the 3-item BCSS [23,24] and rescue
medication use.
During clinic visits, patients completed the St. George’s
Respiratory Questionnaire (SGRQ) [25]. Those in the
Mpex trial completed the Modified Medical Research
Council (mMRC) scale [26], and patients in AZ 1 com-
pleted the Functional Performance Inventory – Short
Form (FPI-SF), evaluating the ease or difficulty with which
they perform daily activities across 6 domains [27,28].Spirometry and exercise tolerance
At enrolment and subsequent clinic visits, spirometry
and exercise tolerance tests (6-minute walk distance
[6MWT] [Mpex and AZ 1] or incremental shuttle walk
[ISWT] [AZ 2]) were performed.
Analyses
A statistical analysis plan was developed for each dataset
prior to analyses. Minimum data requirements were at
least 4 days of baseline diary data (Day −7 to Day −1)
and ≥80% of diary compliance for the period baseline to
end of study or early termination date. Tests were per-
formed on daily (Day −1) and mean weekly (Day −7 to
Day −1) E-RS scores. Because results were consistent,
results for mean weekly scores are reported unless
otherwise specified. Analyses were performed with SAS/
STAT software version 9.2 of the SAS System for PC
(SAS Institute; Cary, North Carolina).
Internal consistency reliability of each E-RS scale was
assessed using Cronbach’s alpha. Intraclass correlation
coefficients (ICC) were used to evaluate reproducibility
during trial run-in periods, Day −7 and Day −1, assum-
ing symptomatic stability across these 2 observations.
The daily global health assessments in the Mpex diary
permitted 2-day test-retest analyses (Days 1–2) in the
subset of patients reporting no change in lung condition.
Paired t-tests and effect sizes (ES) were used to further
understand E-RS score reproducibility.
Validity was assessed by examining the relationship
between baseline E-RS scores and the following criteria,
with variables determined by trial-specific data—airway
obstruction: FEV1% predicted (all trials); respiratory
symptom severity: BCSS (AZ 1, AZ 2); mMRC (Mpex);
rescue medication use (AZ 1, AZ 2); health status:
SGRQ (all trials); functional performance: FPI-SF (AZ 1);
exercise capacity: 6MWT (Mpex, AZ 1) and ISWT (AZ 2).
Spearman’s rho was used for analyses of correlation. Ana-
lysis of covariance (ANCOVA) was used to test E-RS score
differences across mMRC classification; student’s t-test was
used to test scores by rescue medication use at baseline
(none versus ≥3 puffs per day averaged over 7 days).
Tests of responsiveness were conducted in sub-groups
of patients experiencing improvements from baseline to
3 months using the following indicators and their re-
spective responder definitions: health status (SGRQ ≥4
points) [29], symptoms (BCSS ≥1 point) [24], and exer-
cise capacity (6MWT ≥26 meters or ISWT ≥47.5 me-
ters) [30,31]. E-RS score changes were expressed in
terms of mean (SD) and magnitude (percent and ES).
Exploratory analyses examining E-RS score changes in
subjects experiencing health status deterioration (SGRQ
and BCSS) over 12 weeks were also performed.
Criterion-based values were examined in conjunction
with distribution-based estimates (1/2 standard deviation
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responder definitions, i.e., threshold estimates for mean-
ingful symptomatic improvement. Descriptive statistics
were used to examine magnitude of symptomatic (E-RS)
change in responders and non-responders (mean and
percent change, ES) using the proposed threshold, with
figures showing mean (SD) weekly change over 12 weeks
by responder status. Threshold estimates were also ex-
amined in non-responders showing symptomatic decline
over this period.Results
Sample
Sample demographic and clinical characteristics by study
are shown in Table 1. Of those randomized, 235 (78%)
[Mpex], 749 (89%) [AZ 1], and 597 (97%) [AZ 2] met the
minimum data requirements for analysis. eDiary compli-
ance rates from baseline to final visit for the 3 analytical
samples were 87%, 94%, and 97%, respectively.Reliability
Internal consistency levels (Cronbach’s alpha) and repro-
ducibility (ICC) for RS-Total and subscales are shown in
Table 2. Weekly internal consistency levels exceeded
0.90 for the RS-Total, RS-Breathlessness, and RS-Chest
Symptoms scales. The RS-Cough and Sputum subscale
exceeded 0.70 [32,33] in 2 of the 3 trials. Two-day ICC
levels in patients reporting no change (Mpex data) were
greater than 0.80. Reproducibility estimates for the 6-day
pre-treatment interval exceeded the recommended 0.6
threshold [34] in 11 of the 12 tests. The one exception
was the RS-Cough and Sputum score in the Mpex studyTable 2 Internal consistency and reliability
Reliability parameter Mpex
(N = 235)
Internal consistency* Daily† Weekly‡
RS-Total Score 0.88 0.90
RS-Breathlessness 0.89 0.93
RS-Cough and Sputum 0.40 0.52
RS-Chest Symptoms 0.92 0.96
Reproducibility of daily scores§ Day 1–2 Day −7 to −1
(N = 170) (N = 235)
RS-Total Score 0.91 0.71
RS-Breathlessness 0.87 0.73
RS-Cough and Sputum 0.84 0.58
RS-Chest Symptoms 0.89 0.69
*Cronbach’s alpha.
†Day −1.
‡Day −7 to Day −1.
§ICC, random-effects model, Day −7 to Day −1.
Abbreviations: AZ AstraZeneca, ICC intraclass correlation coefficient, N/A not availabl(ICC = 0.58; mean difference [SD] =0 [1.68] p = 0.75;
ES = −0.02) (see Additional file 1: Tables E1–E3).
Validity
Results of tests of construct validity are shown in Tables 3
and 4. E-RS scores were significantly correlated with indi-
cators of airway obstruction, respiratory symptom severity,
rescue medication use, health status, functional perform-
ance, and exercise tolerance. Among subscales, FEV1%
predicted, mMRC, rescue medication use, exercise cap-
acity, and functional performance were most strongly
related to RS-Breathlessness.
Known-groups validity, evaluating E-RS scores by mMRC
dyspnoea level (Mpex) and rescue medication use (AZ 1
and 2) at baseline, is shown in Figure 1. As expected,
the strongest relationship was with RS-Total and RS-
Breathlessness scores.
Responsiveness
Figure 2 displays E-RS score changes by improvement
indicator and trial. For patients whose health status im-
proved from baseline to 3 months, RS-Total scores de-
clined (i.e., improved) by an average of −2.5 to −3.4 on
the 40 point scale, corresponding to 13% to 18% symp-
tomatic change (ES = 0.41 to 0.61). Mean improvements
in RS-Total score corresponding to BCSS changes ≥1
[24] exceeded −6 points (34%, ES > −1.0). Symptomatic
improvement in patients showing improvements in ex-
ercise capacity ranged from −0.6 (2% change, ES 0.12)
to −3.3 points (15% change, ES 0.52). E-RS subscales
(Figure 2B to 2D) showed similar patterns within and
across indicators. Responder estimates using distribution-
based methods are shown in Table 5. Results ofAZ 1 AZ 2
(N = 749) (N = 597)
Daily† Weekly‡ Daily† Weekly‡
0.92 0.94 0.92 0.95
0.90 0.94 0.90 0.94
0.68 0.73 0.71 0.78
0.89 0.94 0.87 0.93
Day −7 to −1 Day −7 to −1
(N = 715) (N = 597)
N/A 0.74 N/A 0.74
N/A 0.71 N/A 0.74
N/A 0.71 N/A 0.69
N/A 0.71 N/A 0.69
e (no global assessment of day-to-day stability).
Table 3 Correlations† between E-RS scores and airway obstruction, respiratory symptom severity, and rescue
medication use










score§ (N = 735)
Rescue
medication









use§ (N = 597)
E-RS Scores
RS-Total Score −0.19** 0.40*** −0.14*** 0.89*** 0.43*** −0.15*** 0.89*** 0.42***
RS-Breathlessness −0.32*** 0.46*** −0.17*** 0.80*** 0.42*** −0.21*** 0.77*** 0.43***
RS-Cough and
Sputum
−0.05 0.16* −0.12*** 0.89*** 0.38*** −0.06 0.92*** 0.33***
RS-Chest Symptoms 0.03 0.27*** −0.07* 0.75*** 0.33*** −0.09* 0.79*** 0.36***
†Spearman's rank-order correlation; E-RS mean weekly scores at baseline (Day −7 to Day −1).
‡Clinic visit, Day 1, prior to treatment.
§Diary: BCSS scores at baseline (Day −7 to Day −1); rescue medication (baseline, Day −1).
Bold coefficients identify constructs with strongest expected relationship.
*p < 0.05; **p < 0.01; ***p < 0.001.
Abbreviations: AZ AstraZeneca, BCSS Breathlessness, Cough and Sputum Scale, E-RS Exacerbations of Chronic Pulmonary Disease Tool – Respiratory Symptoms,
FEV1 forced expiratory volume in 1 second, mMRC modified Medical Research Council dyspnoea scale.
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subjects experiencing health status deterioration from
baseline to week 12 are shown in Additional file 1: Tables
E5 and E6.
Discussion
Determining the extent to which interventions provide
respiratory symptom relief requires randomized trials
with precise endpoint measurement. Comparing treat-
ment effects across studies, e.g., meta-analysis, requires
comparable metrics. To date, there has been no stan-
dardized, reliable, and valid diary for evaluating the
cardinal respiratory symptoms of COPD developed with
regulatory standards for drug development tools in mind
[17-19]. This paper describes the performance of the
E-RS in 3 independent, international RCTs of stable,
symptomatic patients with moderate to severe airway










RS-Total Score 0.65** −0.30*** 0.52**
RS-Breathlessness 0.60** −0.33*** 0.54**
RS-Cough and Sputum 0.45** −0.14* 0.42**
RS-Chest Symptoms 0.50** −0.17** 0.40**
†Spearman's rank-order correlation; E-RS mean weekly scores (Day −7 to Day −1).
‡Clinic visit, Day 1, prior to treatment.
Bold coefficients identify constructs with strongest expected relationship.
*p < 0.05; **p < 0.01; ***p < 0.001.
Abbreviations: 6MWT 6-minute walk test, AZ AstraZeneca, E-RS Exacerbations of Chro
Performance Inventory – Short Form, ISWT Incremental Shuttle Walk Test, SGRQ St.
Questionnaire for COPD.RS-Total and subscale scores exhibited evidence of
reliability, validity, and responsiveness in each trial. Reli-
ability was estimated using tests of internal consistency,
a measure of scale coherence, and reproducibility over
time. Across studies, estimates were strong, exceeding
the 0.70 target for use in clinical trials [32,35] and the
more conservative 0.80 standard [33], suggesting E-RS
scores are precise, with relatively low levels of measure-
ment error. With one exception, values were similar to
those reported previously [20]. The exception was the
internal consistency estimates for the RS-Cough and
Sputum in the Mpex sample (ICC for daily measure-
ments 0.40; 0.52 weekly). This provides an interesting
case study for reliability estimation. It is well known,
and a function of the formula for coefficient alpha, that
reliability is a characteristic of the scale scores in a study
population. An inclusion criterion for the Mpex trial was










−0.14*** −0.43*** 0.51** −0.18***
−0.15*** −0.47*** 0.52** −0.19***
−0.10** −0.28*** 0.41** −0.12**
−0.10** −0.28*** 0.44** −0.15***
nic Pulmonary Disease Tool – Respiratory Symptoms, FPI-SF Functional
























































Figure 1 E-RS Scores by Level of Dyspnoea and Rescue Medication Use. A: Level of Dyspnea (mMRC†). †Mpex data only; E-RS mean weekly
scores (Day −7 to Day −1); ANCOVA controlling for age, co-morbidity, and baseline FEV1. ***p < 0.001; ****p < 0.0001 from global test of differences
between levels. Abbreviations: ANCOVA= analysis of covariance; E-RS = Exacerbations of Chronic Pulmonary Disease Tool – Respiratory Symptoms;
FEV1 = forced expiratory volume in 1 second; mMRC =modified Medical Research Council dyspnoea scale. B: Rescue Medication Use
†. †Results for AZ 1
data shown; similar results were found in AZ 2 data; E-RS and rescue medication use are mean weekly values (Day −7 to Day −1); Students t-test.
****p < 0.0001. Abbreviations: AZ = AstraZeneca; E-RS = Exacerbations of Chronic Pulmonary Disease Tool – Respiratory Symptoms.
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ple reported that it was extremely difficult to bring up
mucus (phlegm); for comparison purposes, the ceiling
effect for this item was observed in less than 2% of the
other 2 samples. Ceiling effects in one variable will at-
tenuate correlations that include this variable and hencereduce reliability coefficients. Thus, the lower coefficient
for internal consistency in the RS-Cough and Sputum
scale in the Mpex study sample is consistent the sputum
severity characteristics of this sample. A drug that eased
difficulty coughing up sputum should lead to a down-
ward shift (improvement) in this aspect of cough and
%
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Figure 2 E-RS Score Improvements by Health Status, Respiratory Symptom, or Exercise Capacity Improvement at 3 Months. A: RS-Total.
*Data from one subject with an extreme positive (worse) E-RS Cough & Sputum score (8 SD) removed from the analysis. Abbreviations:
6MWT = 6-minute walk test; AZ = AstraZeneca; BCSS = Breathlessness, Cough and Sputum Scale; ISWT = Incremental Shuttle Walk Test;
SGRQ = St. George’s Respiratory Questionnaire. B: RS-Breathlessness. *Data from one subject with an extreme positive (worse) E-RS Cough &
Sputum score (8 SD) removed from the analysis. Abbreviations: 6MWT = 6-minute walk test; AZ = AstraZeneca; BCSS = Breathlessness,
Cough and Sputum Scale; ISWT = Incremental Shuttle Walk Test; SGRQ = St. George’s Respiratory Questionnaire. C: RS-Cough and Sputum.
*Data from one subject with an extreme positive (worse) E-RS Cough & Sputum score (8 SD) removed from the analysis. Abbreviations:
6MWT = 6-minute walk test; AZ = AstraZeneca; BCSS = Breathlessness, Cough and Sputum Scale; ISWT = Incremental Shuttle Walk Test;
SGRQ = St. George’s Respiratory Questionnaire. D: RS-Chest Symptoms. *Data from one subject with an extreme positive (worse) E-RS Cough
& Sputum score (8 SD) removed from the analysis. Abbreviations: 6MWT = 6-minute walk test; AZ = AstraZeneca; BCSS = Breathlessness,
Cough and Sputum Scale; ISWT = Incremental Shuttle Walk Test; SGRQ = St. George’s Respiratory Questionnaire.
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treme difficulties. The subscale should also show higher
reliability levels with effective treatment, as the ceiling
effect for this item is reduced or eliminated and equili-
brated across the items comprising the scale.
The 2-day test-retest estimates in the Mpex data indi-
cate consecutive daily scores are reproducible in patients
who report no change in their lung condition over
2 days. The lower estimates observed over a 6-day inter-
val in all subjects during the pre-randomization baseline
run-in suggest some degree of variability in patients
assumed to be stable over this period. Similar patternswere observed in the initial testing of E-RS scores [20].
Together, these results indicate a diary capturing symp-
tom severity each day and averaged over time would be
more accurate than periodic symptom assessments with
longer recall periods commonly used in health status
questionnaires, such as the SGRQ or Chronic Respira-
tory Questionnaire (CRQ) [36]. This not only enhances
the precision of symptom severity estimates and treat-
ment effects, but permits study of day-to-day symptom
variability, an area in need of further research.
The magnitude and pattern of correlations and known-
group differences were consistent with what would be
Table 5 E-RS Responder estimates using distribution-
based methods by trial: ½ SD and SEM*
Scale Method† Mpex AZ 1 AZ 2
(N = 235) (N = 749) (N = 597)
RS-Total
½ SD 2.97 3.00 2.995
SEM 1.88 1.47 1.34
RS-Breathlessness
½ SD 2.97 1.59 1.56
SEM 1.57 0.78 0.76
RS-Cough and Sputum
½ SD 1.04 0.78 0.80
SEM 1.44 0.81 0.75
RS-Chest Symptoms
½ SD 1.04 0.97 0.96
SEM 0.42 0.47 0.51
*SEM ¼ SD ﬃﬃﬃﬃﬃﬃﬃﬃ1−αp .
†Weekly scores at baseline, Day −7 to Day 1; Ranges: RS-Total: 0 to 40;
RS-Breathlessness: 0 to 17; RS-Cough and Sputum: 0 to 11; RS-Chest
Symptoms: 0 to 12; higher scores =more severe symptoms.
Abbreviations: AZ AstraZeneca, E-RS Exacerbations of Chronic Pulmonary
Disease Tool – Respiratory Symptoms, SD standard deviation, SEM standard
error of measurement.
Leidy et al. Respiratory Research 2014, 15:124 Page 8 of 10
http://respiratory-research.com/content/15/1/124expected of a valid patient-reported measure of respiratory
symptoms. Coefficients were highest in tests of concurrent
validity, i.e., between E-RS and BCSS scores, since both
measure respiratory symptoms. In tests of convergent
validity, E-RS and SGRQ health status scores were also
strongly and consistently correlated across the 3 trials, al-
though somewhat weaker than in the initial development
study (0.75, 0.69, 0.58, 0.52 for RS-Total and subscale
scores, respectively [20]). Another widely used measure of
health status, the COPD Assessment Test (CAT) [37] was
not administered in these trials; given the strong relation-
ship between the SGRQ and CAT (e.g., r = 0.69 to 0.87)
[38], one would expect the E-RS and CAT to be highly
correlated as well. The E-RS should be complementary to
heath status questionnaires such as the SGRQ, CAT, and
CRQ in clinical trials since it captures day-to-day severity
and variability of the cardinal respiratory symptoms of
COPD with minimal recall bias and with content, subscale
structure, and scores that capture these symptoms. To
optimize data quality, particularly over lengthy trials, the
E-RS should be completed as part of the EXACT, on a
pretested, user-friendly electronic device programmed
with reminders; subjects should be trained on the device
and monitored for compliance during the course of the
study [39].
Patients with more severe symptoms reported poorer
functional performance, as measured by the FPI-SF. In
keeping with divergent validity, correlations between re-
spiratory symptoms and airway obstruction (FEV1% pre-
dicted) were weak, although statistically significant. Ofthe 3 subscales, RS-Breathlessness was consistently the
strongest correlate of FEV1% predicted, mMRC, rescue
medication use, and functional performance, all indicators
or effects of dyspnoea. This is consistent with convergent
validity for RS-Breathlessness and divergent validity for
RS-Cough and Sputum and RS-Chest Symptoms.
E-RS scores were sensitive to change in patients
showing improvement in health status (3 of 3 studies),
symptoms (2 of 2 studies) or exercise tolerance (3 of 3
studies) from baseline to month 3. Exploratory analyses
suggest E-RS scores are also sensitive to symptomatic
worsening over 12 weeks.
In the initial testing of the E-RS, only distribution-
based methods (½ standard deviation of baseline values)
were available for responder definitions of symptomatic
improvement; these gave values of: RS-Total: 3.35; RS-
Breathlessness: 1.85; RS-Cough and Sputum: 1.15; and
RS-Chest Symptoms: 1.05 [20]. Such methods are largely
unvalidated in terms of their relationship to the patient’s
actual experience and may give values higher than the
“true” responder threshold [40]. The current set of
analyses support this caveat; the initial estimates should
be interpreted as moderate to large, and not as minimal.
Based on results from these 3 trials, across criterion-
variable and distribution-based methods, variable and
distribution-based methods, the following responder
definitions for symptomatic improvement are proposed:
RS-Total ≥ −2.0 (scale range: 0–40)
RS-Breathlessness ≥ −1.0 (scale range: 0–17)
RS-Cough and Sputum ≥ −0.70 (scale range 0–11)
RS-Chest Symptoms ≥ −0.70 (scale range: 0–12)
Descriptive statistics and figures showing E-RS change
scores over 12 weeks for responders and non-responders
are provided in Additional file 1: Table E4 and Figures
E1a–E1d. Results of the exploratory analyses suggest
symmetric thresholds for symptomatic improvement and
decline (i.e., applying ≥ + 2.0; ≥ + 1.0; ≥ + 0.70; ≥ + 0.70
for Total and subscale scores, respectively for symptom
worsening) (see Additional file 1: Tables E5 and E6).
Given the magnitude of symptomatic improvement in
responders and symptomatic decline in those whose
symptoms worsened, these definitions may also be con-
servative estimates. Further research is needed in studies
with global ratings of change, compounds showing
treatment effects in several efficacy endpoints, including
respiratory symptoms, and longer studies in patients at
risk of decline.
Although the results presented here provide evidence
that E-RS scores are reliable, valid, and sensitive to change
in international RCT settings, several limitations should
be noted. First, because the experimental drugs showed
no therapeutic effects, responsiveness to treatment relative
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http://respiratory-research.com/content/15/1/124to placebo could not be evaluated. Tests of sensitivity to
change and responder definitions were based on changes
observed in criterion variables generally associated with
symptomatic change. Results reported by Beier et al. [41]
indicate E-RS scores are sensitive to symptomatic im-
provement with effective treatment over 6 weeks. In that
trial, significant within- and between- group treatment
effects were observed for aclidinium bromide and tiotro-
pium versus placebo (E-RS-Total, RS-Breathlessness, and
RS Chest Symptoms; significant effects for RS-Cough and
Sputum for aclidinium only).
A second limitation is related to the study samples.
Each trial enrolled symptomatic and clinically stable
patients, consistent with the target population for the
measure. In addition, the inclusion criteria specified a
history of 1 or more clinic visits or hospitalizations for
COPD exacerbation the prior 12 months. Although it is
reasonable to expect the E-RS to perform similarly in
patients without this history, further study should be
undertaken to test this assumption. Finally, these trials
were limited to 3 to 6 months; longer studies would
permit an evaluation of the patterns and persistence of
symptomatic improvement and worsening, including
further study of thresholds for meaningful improvement
and deterioration.Conclusion
The E-RS provides a reliable, valid, and responsive method
for quantifying respiratory symptom severity in clinical
studies of COPD. Because the 11-item E-RS is embedded
in the 14-item EXACT, a single diary can be used to evalu-
ate the effects of treatment on day-to-day symptom severity
in stable disease, using E-RS scores, and on acute exacerba-
tions of COPD using the EXACT scoring algorithms.Additional file
Additional file 1: Showing E-RS score reproducibility (test-retest)
results; one table and one set of figures showing E-RS scores over
time in responders and non-responders; two tables and a description
of symptomatic change in subjects (non-responders) with indication
of worsening; and a detailed description of the E-RS instrument.Competing interests
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